PDS Biotechnology Corporation (PDSB) Reports -65.58% Fall From For 52 Week High, It’s Always Darkest Before The Dawn

PDS Biotechnology Corporation (NASDAQ:PDSB) does about 949.98K shares in volume on a normal day but saw 713619 shares change hands in Tuesday’s trading. The company now has a market cap of 129.66M USD. Its current market price is $3.54, marking a decrease of -1.53% compared to the previous close of $3.59. The 52 week high reached by this stock is $10.27 whilst the lowest price level in 52 weeks is $2.59.

PDS Biotechnology Corporation (PDSB) has a 20-day trading average at $3.41 and the current price is -65.58% off the 52-week high compared with 36.49% distance from its 52-week low. The 50-day simple moving average of the closing price is $3.92 and its 200-day simple moving average is $4.90. If we look at the stock’s price movements over the week, volatility stands at 12.66%, which decreases to 9.31% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 47.85 to suggest the stock is neutral.

The consensus objective for the share price is $15.00, suggesting that the stock has a potential upside of 76.4% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on November 01, 2022 when B. Riley Securities initiated the stock to “Buy” and issued a price target of $10. H.C. Wainwright upgraded its price target at $6.

PDS Biotechnology Corporation (PDSB) stock is down -6.36% over the week and 25.35% over the past month. Its price is -28.87% year-to-date and -45.19% over the past year.

The stock last released its quarterly earnings report for quarter ended 12/31/2023, with the company’s earnings per share (EPS) of -0.32 below consensus estimates by -0.01. The company’s next earnings report forecasts estimating quarterly EPS at -0.37 and -1.51 for whole year.

To reach the target analysts have set, the stock logically needs to grow 76.4 percent from here.

The company has a return on investment of -93.84% and return on equity of -122.46%. The beta has a value of 1.87. Price to book ratio is 4.48.